Which hedge funds own SUPN? SUPERNUS PHARMACEUTICALS, Q2 2026 13F holders
41 tracked hedge funds disclosed a position in SUPN (SUPERNUS PHARMACEUTICALS) in their Q2 2026 13F filings, worth $750.8m in total. The largest holder by portfolio weight is Krensavage Asset Management, LLC at 5.0% of its book. 10 opened a new position this quarter: Soleus Capital Management, L.P., Hillsdale Investment Management Inc., Edgestream Partners, L.P., Entropy Technologies, LP. 9 exited: Catalio Capital Management, LP, Parkman Healthcare Partners LLC, Verdad Advisers, LP.
- 41
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 10
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 9
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $35.9m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $83.2m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $751m
- Combined value Sum of the holders' reported positions in the security.
- 3.3%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Catalio Capital Management, LP | 0.7% | $3.2m |
| Parkman Healthcare Partners LLC | 0.5% | $4.4m |
| Verdad Advisers, LP | 0.4% | $325k |
| Point72 Asset Management, L.P. | 0.1% | $68.2m |
| Fox Run Management, L.L.C. | 0.1% | $640k |
| Twinbeech Capital LP | 0.1% | $982k |
| Hudson Bay Capital Management LP | 0.03% | $4.7m |
| Walleye Capital LLC | 0.0% | $580k |
| Farallon Capital Management, L.L.C. | 0.0% | $207k |
Ownership over time
Who discovered SUPN first? Beta
The run: Q1 2016 → Q2 2018, +292%
| Armistice Capital, LLC high conviction | Q4 2019 | – | +4.9 pts |
| Krensavage Asset Management, LLC high conviction | Q1 2025 | – | +3.7 pts |
| Opaleye Management Inc. | Q1 2015 | 1.2% | +1.8 pts |
| Ardsley Advisory Partners LP | Q4 2013 | – | +1.5 pts |
| Pura Vida Investments, LLC | Q1 2017 | – | +0.9 pts |
| Sofinnova Investments, Inc. | Q2 2025 | – | +0.6 pts |
| Parkman Healthcare Partners LLC | Q2 2021 | – | −0.1 pts |
| Soleus Capital Management, L.P. | Q1 2022 | – | −0.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.